-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Sichuan Proud Times Pharmaceutical's lanthanum carbonate chewable tablets were approved for production in Class 4 imitations
.
According to data from Minet.
com, the sales of lanthanum carbonate chewable tablets in China's public medical institutions exceeded 300 million yuan in 2020, with a year-on-year increase of nearly 50% in the first half of 2021
.
Sales of lanthanum carbonate chewable tablets in public medical institutions in China in recent years (unit: 100 million yuan) Source: Terminal competition in public medical institutions in China Lanthanum carbonate is a calcium-free and resin-free phosphate binder developed by Shire, which is mainly used to control acceptance Hyperphosphatemia in dialysis-treated chronic renal failure patients
.
According to the data of Minet.
com, in recent years, the sales of terminal lanthanum carbonate chewable tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have risen rapidly, exceeding 300 million yuan in 2020, and will be released in 2021.
With an increase of nearly 50% year-on-year, Shire has the largest market share
.
Source: One-click retrieval on Minet.
Before that, there were only two manufacturers of lanthanum carbonate chewable tablets.
Hunan Mingrui Pharmaceutical won the first imitation in February 2020, but there was no review
.
A few days ago, Sichuan Proud Times Pharmaceutical Co.
, Ltd.
was approved as a 4-type imitation product, which is regarded as a review.
It is also the first company to review this product
.
Supplementary application for production and consistency evaluation of lanthanum carbonate chewable tablets under review Source: MED2.
0 China Drug Evaluation Database of Minet Qing Pharma and Shenyang Funing Pharma reported production as Generic Category 4, and they were deemed to be over-evaluated after approval; Hunan Mingrui Pharma's supplementary application for consistency evaluation is under review and approval
.
Source: State Food and Drug Administration official website, Minet database
.
According to data from Minet.
com, the sales of lanthanum carbonate chewable tablets in China's public medical institutions exceeded 300 million yuan in 2020, with a year-on-year increase of nearly 50% in the first half of 2021
.
Sales of lanthanum carbonate chewable tablets in public medical institutions in China in recent years (unit: 100 million yuan) Source: Terminal competition in public medical institutions in China Lanthanum carbonate is a calcium-free and resin-free phosphate binder developed by Shire, which is mainly used to control acceptance Hyperphosphatemia in dialysis-treated chronic renal failure patients
.
According to the data of Minet.
com, in recent years, the sales of terminal lanthanum carbonate chewable tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have risen rapidly, exceeding 300 million yuan in 2020, and will be released in 2021.
With an increase of nearly 50% year-on-year, Shire has the largest market share
.
Source: One-click retrieval on Minet.
Before that, there were only two manufacturers of lanthanum carbonate chewable tablets.
Hunan Mingrui Pharmaceutical won the first imitation in February 2020, but there was no review
.
A few days ago, Sichuan Proud Times Pharmaceutical Co.
, Ltd.
was approved as a 4-type imitation product, which is regarded as a review.
It is also the first company to review this product
.
Supplementary application for production and consistency evaluation of lanthanum carbonate chewable tablets under review Source: MED2.
0 China Drug Evaluation Database of Minet Qing Pharma and Shenyang Funing Pharma reported production as Generic Category 4, and they were deemed to be over-evaluated after approval; Hunan Mingrui Pharma's supplementary application for consistency evaluation is under review and approval
.
Source: State Food and Drug Administration official website, Minet database
